ViaCyte to Present Plenary Lecture at ISSCR 2015 Annual Meeting
SAN DIEGO, June 16, 2015 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a company presentation at the 13th Annual Meeting of the International Society for Stem Cell Research (ISSCR).
Allan Robins, Ph.D., Senior Vice President of Science and Technology, will review recent progress with the company’s VC-01™ product candidate for the treatment of type 1 diabetes, which entered the clinical phase of development late last year. The Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type One Diabetes, is ongoing.
Details of the events are as follows:
Session: Plenary V – Therapy with Stem Cells
Date/Time: June 26, 2015 at 16:00
Location: Stockholmsmässan Exhibition and Convention Center, Stockholm, Sweden
Dr. Robins will also co-lead the ISSCR Workshop on Clinical Translation:
Date/Time: June 23, 2015 at 09:00 – 18:00
Location: Karolinska Institutet, Huddinge Campus, Stockholm, Sweden
For more information about ViaCyte’s participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/
ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes. ViaCyte is conducting a Phase 1/2 clinical trial of the Company’s lead VC-01 product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte’s VC-01 combination product candidate is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells. These progenitor cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. The VC-01 product candidate is being developed as a potential long-term diabetes treatment without immune suppression, and without risk of hypoglycemia or other diabetes-related complications.
ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.